The Danish Health and Medicines Authority wishes to inform future applicants of the possibility to request for a time slot to applications for marketing authorisations through the decentralised procedure (DCP) where Denmark is acting as reference member state (RMS).
About the decentralised procedure
The decentralised procedure (DCP) is one of four ways in which companies can apply for authorisation to market medicines in Denmark and the EU/EEA.
The decentralised procedure in which companies can apply for authorisation in more than one EU or EEA country simultaneously and where no EU or EEA country has granted a national authorisation in advance.
The Reference Member State (RMS) is responsible for the procedure and the scientific evaluation of the application.